Definitive Proxy Filed for Redx Reverse Merger — Skye Holders Left with Just 5.38%
SKYE sits 81% above its 52-week low of $0.276 on elevated volume (3.9× avg).
Summary
Definitive proxy materials for the reverse merger with Redx Pharma have been filed. Skye shareholders will own just 5.38% of the combined company, with Redx holders at 46.17% and new investors at 48.45%. The deal includes $103.9M in financing and a 1-for-8 reverse stock split.
Key Events · M&A and Partnerships · SKYE
-
Reverse Merger with Redx Pharma
Skye will acquire Redx Pharma via a UK scheme of arrangement. Ownership of the combined company will be split with Skye shareholders at only 5.38%, Redx holders at 46.17%, and new investors at 48.45%.
-
Valuation Disparity
The valuation gap is significant: Skye is valued at $14.5M (subject to a $2M floor) while Redx is valued at $125M, underscoring Redx's dominance in the combined entity.
-
Financing Package
The financing package includes a $67.9M concurrent financing (up to $72.9M), a $36M Series A financing, a $22M equity line of credit, and a $5M warrant to Redmile Group.
-
1-for-8 Reverse Stock Split
A 1-for-8 reverse stock split takes effect August 24, 2026, reducing authorized shares from 300M to 37.5M and outstanding shares from 35.4M to approximately 4.4M.
Analysis · SKYE · Life Sciences
The definitive proxy materials for the reverse merger with Redx Pharma have been filed, and the ownership math is stark: Skye shareholders will retain only 5.38% of the combined company, while Redx holders claim 46.17% and new investors take 48.45%. The full Transaction Agreement reveals a $14.5M valuation for Skye against $125M for Redx, alongside a $67.9M concurrent financing, a $36M Series A financing, a $22M equity line, and a 1-for-8 reverse stock split effective August 24, 2026. This is a transformative event that fundamentally reshapes Skye's ownership and future.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.6M. The 52-week trading range was $0.28 to $4.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.